The interplay between HT, density, and breast cancer

Article

Citing density's masking effects on mammography in his presentation at the NAMS meeting, Bo von Schoultz, MD, PhD, said breast density may be a target for intervention by lowering doses of postmenopausal women's hormone therapy.

Citing density's masking effects on mammography in his presentation at the NAMS meeting, Bo von Schoultz, MD, PhD said breast density may be a target for intervention by lowering doses of postmenopausal women's hormone therapy. "The most density will occur with long-term standard combined hormone therapy," he said, "although every individual has her own baseline density. A significant portion will get a major density when taking hormones; others respond very little." However, as shown by the estrogen-only arm of the Women's Health Institute study, there may be a reduced risk when taking estrogen without a progestin.

Hence the need for safer regimens, reflected in the subject of his talk: "Lowering the dose of EPT: Efficacy and safety." Dr. von Schoultz shared results of a study of a subpopulation of 255 postmenopausal women from Nordic countries in the CHOICE trial, for which mammograms were done before the participants began treatment and after 5 to 6 months.

The study compared the effects of two low-dose combinations of estrogen and progestogen therapy: 0.5 mg estradiol (E2) plus 0.25 mg or 0.1 mg of norethindrone acetate and placebo, on mammographic density. Using the Wolfe classification and two other methods, no increase in breast density was found in any study group. "Although our results seem promising, this was a secondary objective of this study, so larger prospective studies are needed to confirm this new finding," he concluded.

Boyd NF, Fuo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227-236.

Lundstrom E, Bygdeson M, Svane G, et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density.

Related Videos
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Enhancing cervical cancer management with dual stain | Image Credit: linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
Understanding the impact of STIs on young adults | Image Credit: providers.ucsd.edu.
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Related Content
© 2024 MJH Life Sciences

All rights reserved.